How Regulatory Changes Are Driving The Future Of The Medical Device Industry

Report

How Regulatory Changes Are Driving The Future Of The Medical Device Industry

With new entrants from emerging countries giving the established brands a run for their money, the medical device market has become more competitive. ...

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

White paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

Growing Attention Being Paid To Pharma Company Rebates And Discounts

White paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

Perspectives On Pharma Company Use Of Open Payments Data

White paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

White paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

White paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

Deploying Successful Global Incentive Compensation Capabilities

White paper

Deploying Successful Global Incentive Compensation Capabilities

There exists no single formula to solve the incentive compensation management puzzle, especially at a global scale across multiple geographies. The answer lies in a global IC plan ...

The Causes and Solutions of Chronic Drug Shortages in the United States

Article

The Causes and Solutions of Chronic Drug Shortages in the United States

While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...

Aligning Sales to the Field Force with Accurate IC Sales Crediting

White paper

Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape

With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...

Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

White paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

Evolution of Pharmaceutical Call Planning

White paper

Evolution of Pharmaceutical Call Planning

This white paper will explore the factors used to develop account based call plans and how pharmaceutical companies’ must adapt to ensure their representatives are prepared and q ...

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

White paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

White paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

White paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

White paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

White paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

State Of Commercial Excellence 2017 - Part 1

Industry Survey

State Of Commercial Excellence 2017 – Part 1

Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

White paper

Is it Time to Adjust the Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – Is it time to adjust the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE ...

Make US Pharma Great Again!? - Part 1

Whitepaper

Make US Pharma Great Again!? – Part 2

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry.This comes ...

Make US Pharma Great Again!? - Part 1

White paper

Make US Pharma Great Again!? – Part 1

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his ver ...

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

White paper

Latest Pharma R&D Cost Estimates – Implications For The Expanded Use Of Commercial Analytics

The latest pharma R&D cost estimates illustrate that greater pressures will increasingly be placed on companies to find greater cost efficiencies, reduce risks, improve pipelin ...

Biosimilars In The US - Will They Deliver On The Promise?

Blog

Biosimilars In The US – Will They Deliver On The Promise?

Research presented from Mylan Pharmaceuticals at the recently held 2016 annual meeting of the American Society of Clinical Oncology (ASCO) generated excitement within the medical c ...

The Pricing Challenge Of Pharma's Shift To Specialty Medicines

White paper

The Pricing Challenge Of Pharma’s Shift To Specialty Medicines

The shift to specialty medicines has opened up for pharma companies a wealth of opportunities in addressing unmet medical needs of patients and improve the cost of care. This shift ...

White paper

Improve STAR Rating With Analytics Powered Therapy Adherence Strategy

Improving the quality of care and services to patients and enrollees is one of the key imperatives of Affordable Care Act (ACA). Several initiatives and measures have been put in p ...

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

White paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

Growing Attention Being Paid To Pharma Company Rebates And Discounts

White paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

Perspectives On Pharma Company Use Of Open Payments Data

White paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

White paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

White paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

Deploying Successful Global Incentive Compensation Capabilities

White paper

Deploying Successful Global Incentive Compensation Capabilities

There exists no single formula to solve the incentive compensation management puzzle, especially at a global scale across multiple geographies. The answer lies in a global IC plan ...

The Causes and Solutions of Chronic Drug Shortages in the United States

Article

The Causes and Solutions of Chronic Drug Shortages in the United States

While recent empirical research has exposed an array of causes for drug shortages, the application of better analytics has now also been cited as needed to account for these effect ...

Aligning Sales to the Field Force with Accurate IC Sales Crediting

White paper

Aligning Sales to the Field Force – Increasing Complexities with Change in the Pharma Landscape

With this Whitepaper, unravel means of actual and correct sales crediting and therefore reduce pitfalls in incentive payouts through assigning correct addresses, managing shared ta ...

Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

White paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

Evolution of Pharmaceutical Call Planning

White paper

Evolution of Pharmaceutical Call Planning

This white paper will explore the factors used to develop account based call plans and how pharmaceutical companies’ must adapt to ensure their representatives are prepared and q ...

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

White paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

Achieving Sales Operations Excellence With Intelligent Roster Management

White paper

Achieving Sales Operations Excellence With Intelligent Roster Management

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to h ...

How Regulatory Changes Are Driving The Future Of The Medical Device Industry

Report

How Regulatory Changes Are Driving The Future Of The Medical Device Industry

With new entrants from emerging countries giving the established brands a run for their money, the medical device market has become more competitive. ...

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

White paper

Challenges And Opportunities To Commercialize Orphan Drugs For Rare Diseases In The US

This white paper explores the unique challenges of ODs for RDs and the different approaches needed to address specific questions for their successful commercialization that vary fr ...

Growing Attention Being Paid To Pharma Company Rebates And Discounts

White paper

Growing Attention Being Paid To Pharma Company Rebates And Discounts

Pharma companies need to better understand how to manage rebates and discounts, while also developing a broader view of the effect on patients and the healthcare system. ...

Perspectives On Pharma Company Use Of Open Payments Data

White paper

Perspectives On Pharma Company Use Of Open Payments Data

This paper provides a detailed analysis on the role and effects of “Sunshine Laws” and payments made to providers as seen from published empirical evidence, intricacies and cha ...

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

White paper

How Will The 2018 Midterm Congressional Election Results Affect The US Pharma Industry?

The 2018 Congressional midterm elections are over after a bitter political fight. The voters have spoken. We are back to divided government, with Democrats controlling the House, a ...

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

White paper

Is The CVS-Aetna Merger A Pharma Industry Transformative Event?

US antitrust officials recently approved the proposed $69 billion CVS-Aetna merger. This merger follows a similar action taken by the Justice Department to approve the Cigna-Expres ...

Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

White paper

The Value of Machine Learning and Data Mining in Pharmaceutical Commercial Analytics

Increasing complexities of the pharma environment also mean that machine learning can provide earlier anticipation of and faster responses to new threats and opportunities. ...

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

White paper

Are Pharmaceutical Direct-To-Consumer TV Ads Appropriate? A Commentary

No pharmaceutical topic causes as much passionate difference of opinions between industry and medical community representatives as the practice of direct-to-consumer advertising (D ...

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

White paper

Regional Sales And Marketing Optimization Modeling: A Call For Technical Changes

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commer ...

Decision Science Asset Diversification Versus Concentration

White paper

Decision Science Asset Diversification Versus Concentration

The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...

The Reasons for and Solutions to Chronic Drug Shortages in the United States

White paper

The Reasons for and Solutions to Chronic Drug Shortages in the United States

This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...

Pricing and Market Effects of Biosimilar Entry in the US

White paper

Pricing and Market Effects of Biosimilar Entry in the US

This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...

Let us help your business today.
Contact us now to start your journey.